Nectar Lifesciences gets nod to acquire 100% stake in Avensis Export
The proposed acquisition of Avensis Export will help the company to enter into a real estate business
Nectar Lifesciences has received approval to acquire 100% paid-up equity share capital of Avensis Exports (AEPL). The proposed acquisition of AEPL will help the company to enter into a real estate business. AEPL’s exposures in land and collaborations with other real estate companies will help the company to set its footprints in the real estate arena. This investment will allow the company to diversify, strengthen its position in the real estate business. The cost of the said acquisition is Rs 24.96 lakh and is expected to be completed within a period of 1 month.
Post acquisition, AEPL will become a wholly owned subsidiary of the company. The board of directors of the company in its meeting held on March 02, 2026, has, inter-alia, approved the same.
Nectar Lifesciences, Incorporated in 1995, is a leading global manufacturer of cephalosporin antibiotics medicines.
